Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Longeveron Expands Enrollment Criteria for Trial Evaluating Lomecel-B Infusion ARDS due to COVID-19

americanpharmaceuticalreviewMarch 11, 2021

Tag: Longeveron , COVID-19 , ARDS , Lomecel-B

PharmaSources Customer Service